Keloids - Pipeline Insight, 2021
This report can be delivered to the clients within 24 hours
DelveInsight’s, “Keloids - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Keloids pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Keloids: Overview
Keloids are raised overgrowths of scar tissue that occur at the site of a skin injury. They occur where trauma, surgery, blisters, vaccinations, acne or body piercing have injured the skin. Keloid scars tend to be larger than the original wound itself. They are shiny, smooth and rounded skin elevations that may be pink, purple, or brown. Most types of skin injury can contribute to keloid scarring. Keloids should not be confused with hypertrophic scars, which are raised scars that do not grow beyond the boundaries of the original wound and may reduce over time. A dermatologist diagnoses a keloid on the basis of its appearance and a history of tissue injury, such as surgery, acne or body piercing. Available treatments include: Removal with conventional surgery, Dressings, Corticosteroid injections, Compression, Cryosurgery, Radiation therapy, Laser therapy, and Fluorouracil injections.
'Keloids - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Keloids pipeline landscape is provided which includes the disease overview and Keloids treatment guidelines. The assessment part of the report embraces, in depth Keloids commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Keloids collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Keloids report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Keloids Emerging Drugs
Further product details are provided in the report……..
Keloids: Therapeutic Assessment
This segment of the report provides insights about the different Keloids drugs segregated based on following parameters that define the scope of the report, such as:
Keloids: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Keloids therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Keloids drugs.
Keloids Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Keloids - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Keloids pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Keloids: Overview
Keloids are raised overgrowths of scar tissue that occur at the site of a skin injury. They occur where trauma, surgery, blisters, vaccinations, acne or body piercing have injured the skin. Keloid scars tend to be larger than the original wound itself. They are shiny, smooth and rounded skin elevations that may be pink, purple, or brown. Most types of skin injury can contribute to keloid scarring. Keloids should not be confused with hypertrophic scars, which are raised scars that do not grow beyond the boundaries of the original wound and may reduce over time. A dermatologist diagnoses a keloid on the basis of its appearance and a history of tissue injury, such as surgery, acne or body piercing. Available treatments include: Removal with conventional surgery, Dressings, Corticosteroid injections, Compression, Cryosurgery, Radiation therapy, Laser therapy, and Fluorouracil injections.
'Keloids - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Keloids pipeline landscape is provided which includes the disease overview and Keloids treatment guidelines. The assessment part of the report embraces, in depth Keloids commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Keloids collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Keloids R&D. The therapies under development are focused on novel approaches to treat/improve Keloids.
This segment of the Keloids report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Keloids Emerging Drugs
- STP705: Sirnaomics
- LEM-S401: Lemonex
Further product details are provided in the report……..
Keloids: Therapeutic Assessment
This segment of the report provides insights about the different Keloids drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Keloids
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Keloids: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Keloids therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Keloids drugs.
Keloids Report Insights
- Keloids Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Keloids drugs?
- How many Keloids drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Keloids?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Keloids therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Keloids and their status?
- What are the key designations that have been granted to the emerging drugs?
- Yuhan
- Lemonex
- BirchBioMed
- Sirnaomics
- YH-siRNA1
- LEM-S401
- Kynurenic acid
- STP705
Introduction
Executive Summary
Keloids: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Keloids – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
STP705: Sirnaomics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
LEM-S401: Lemonex
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Keloids Key Companies
Keloids Key Products
Keloids- Unmet Needs
Keloids- Market Drivers and Barriers
Keloids- Future Perspectives and Conclusion
Keloids Analyst Views
Appendix
Executive Summary
Keloids: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Keloids – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
STP705: Sirnaomics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
LEM-S401: Lemonex
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Keloids Key Companies
Keloids Key Products
Keloids- Unmet Needs
Keloids- Market Drivers and Barriers
Keloids- Future Perspectives and Conclusion
Keloids Analyst Views
Appendix
LIST OF TABLES
Table 1 Total Products for Keloids
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Keloids
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Keloids
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Keloids
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
